These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18462843)

  • 1. Safety of MF59 adjuvant.
    Schultze V; D'Agosto V; Wack A; Novicki D; Zorn J; Hennig R
    Vaccine; 2008 Jun; 26(26):3209-22. PubMed ID: 18462843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
    Podda A; Del Giudice G
    Expert Rev Vaccines; 2003 Apr; 2(2):197-203. PubMed ID: 12899571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?
    O'Hagan DT; Wack A; Podda A
    Clin Pharmacol Ther; 2007 Dec; 82(6):740-4. PubMed ID: 17971820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT
    Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
    El Sahly H
    Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.
    Pellegrini M; Nicolay U; Lindert K; Groth N; Della Cioppa G
    Vaccine; 2009 Nov; 27(49):6959-65. PubMed ID: 19751689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
    Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.
    Tsai T; Kyaw MH; Novicki D; Nacci P; Rai S; Clemens R
    Vaccine; 2010 Feb; 28(7):1877-80. PubMed ID: 19969117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles.
    O'Hagan DT; Ott GS; Van Nest G
    Mol Med Today; 1997 Feb; 3(2):69-75. PubMed ID: 9060004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
    Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A
    Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
    Puig Barberà J; González Vidal D
    Expert Rev Vaccines; 2007 Oct; 6(5):659-65. PubMed ID: 17931147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.
    Fox CB; Haensler J
    Expert Rev Vaccines; 2013 Jul; 12(7):747-58. PubMed ID: 23885820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination, squalene and anti-squalene antibodies: facts or fiction?
    Lippi G; Targher G; Franchini M
    Eur J Intern Med; 2010 Apr; 21(2):70-3. PubMed ID: 20206873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune hemolytic anemia following MF59-adjuvanted influenza vaccine administration: a report of two cases.
    Montagnani S; Tuccori M; Lombardo G; Testi A; Mantarro S; Ruggiero E; Blandizzi C
    Ann Pharmacother; 2011 Jan; 45(1):e8. PubMed ID: 21189364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
    Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The history of MF59(®) adjuvant: a phoenix that arose from the ashes.
    O'Hagan DT; Ott GS; Nest GV; Rappuoli R; Giudice GD
    Expert Rev Vaccines; 2013 Jan; 12(1):13-30. PubMed ID: 23256736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B; Neri M; Lepri E; Iorio AM
    Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.
    Calabro S; Tritto E; Pezzotti A; Taccone M; Muzzi A; Bertholet S; De Gregorio E; O'Hagan DT; Baudner B; Seubert A
    Vaccine; 2013 Jul; 31(33):3363-9. PubMed ID: 23684834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant.
    Heineman TC; Clements-Mann ML; Poland GA; Jacobson RM; Izu AE; Sakamoto D; Eiden J; Van Nest GA; Hsu HH
    Vaccine; 1999 Jul; 17(22):2769-78. PubMed ID: 10438046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.